Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Advertisement
Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

UAE Slashes Prices For Over 400 Generics

The United Arab Emirates health ministry is cutting the prices of more than 400 generic drugs by as much as 77% as it seeks to reduce rising healthcare costs.

Pricing Strategies Regulation

CC-Pharming And iBio Expand Chinese Rituximab Venture

A year after their initial tie-up, US plant-based tech firm iBio Inc. and China’s CC-Pharming Ltd are expanding their collaboration on developing a plant-derived bio-better rituximab candidate for the Chinese market.

Deals Biosimilars

Strides Grows In Central Europe Through Fairmed Deal

Strides Pharma Science has acquired a majority stake in Swiss generics firm Fairmed Healthcare in a move to bolster its presence in central Europe. The acquisition marks the latest in a string of transactions by the Indian firm.

Deals India

Hong Kong's PAG Acquires $540m Majority Stake In Hisun's Biosimilars Arm

Asia-focused PE firm PAG has purchased a majority stake in Hisun BioRay, the biotech division of Chinese state-owned generic company Zhejiang Hisun Pharmaceutical, for $540m, boosting its presence in a nascent, fast-growing segment of the country’s drug industry.

Deals Biosimilars

PE Interest In Hisun's Biosimilars Arm As Hong Kong Firm Acquires $540m Majority Stake

Asia-focused PE firm PAG has purchased a majority stake in Hisun BioRay, the biotech division of Chinese state-owned generic company Zhejiang Hisun Pharmaceutical, for $540m, boosting its presence in a nascent, fast-growing segment of the country’s drug industry.

China Business Strategies

Glenmark Says Makeover To Be Finished By End 2019-20 As It Seeks To Spur Growth

Glenmark says its reorganization into three entities – one focused on generics and specialty drugs, the second on APIs and the third on new drug innovation – will be wrapped up by year-end as it seeks to accelerate sluggish earnings and reduce heavy debt.

Strategy Sales & Earnings
See All
Advertisement
UsernamePublicRestriction

Register